Publication of first clinical evidence for EHO-85 hydrogel

The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been published in the Journal of Clinical Medicine. The published article refers to an 8‐week, multicentre, randomized  clinical trial  designed to demonstrate the accelerating effect on wound healing of the [...]

Read More

First publication for OLE hydrogel

We are happy to announce the publication in Pharmaceutics of the first paper related to our hydrogel based on Olea europaea leaf extract (OELE) indicated for the healing of wounds of full and partial thickness. The publication is based on a study that has been designed and carried out by several authors who come from different areas of basic [...]

Read More

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children”

Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715. [...]

Read More

Uncomplicated Urinary Tract Infection in Adults – Noventure new Publication

We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention of recurrences in uncomplicated UTIs The trial “Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults“ has [...]

Read More

Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis: a retrospective, observational study

Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Publication of a retrospective, observational study on Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis. Aim: To evaluate the effectiveness and safety of gelatin tannate [...]

Read More

A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis.

Allegrini A et al. Current Medical Research and Opinion 2017.  June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis. Methodology: In this randomized, double-blind study, 40 patients with itching, nasal congestion or continuous sneezing and [...]

Read More

AGA Abstracts Tu1254 – Protective Effect of Mucoprotectants and Prebiotic Combination on Gut Barrier Impairment and Visceral Hypersensitivity Induced by an Acute Stress in Rat

HeleneEutamene, FannyPlacide, ValerieTondereau, VassiliaTheodorou https://doi.org/10.1016/S0016-5085(18)33080-4 BACKGROUND: Irritable Bowel Syndrome (IBS) is a common disorder characterized by visceral hypersensitivity and increased intestinal permeability. Stressful events can affect the onset and course of IBS. In rats, stress also induces visceral hypersensitivity and gut hyperpermeability. Mucoprotectant agents such as gelatin tannate and xyloglucan, [...]

Read More

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.

Octavian Alexea, Vlad Bacarea and Nuria Pique. United European Gastroenterol J. 2016 Jun;4(3):455-65. Background: A medical device containing the film-forming agent reticulated protein and a prebiotic mixture of vegetable oligo- and polysaccharides has been developed, recently receiving European approval as MED class III for the treatment of chronic/functional or recidivant [...]

Read More